May 01, 2016 - MM&M - Medical Marketing and Media

Print Issue: May 01, 2016

5. Pfizer

Pfizer’s dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

17. Mylan

After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

4. Novartis

There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

16. Boehringer Ingelheim

In an effort to overcome pricing pressures and bounce back from patent losses, Germany’s second-largest drugmaker has unloaded assets and reshuffled its management team.